Biomarker-s of Abusive Head Trauma by Proteomics

Launched by UNIVERSITY HOSPITAL, GENEVA · Nov 15, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "Biomarkers of Abusive Head Trauma by Proteomics," aims to identify specific markers in the blood of young children who may have experienced abusive head trauma. The researchers are focusing on understanding these markers through detailed blood tests to help detect potential cases of abuse more effectively.

To be eligible for this study, children aged 0 to 2 years who have received medical attention for symptoms like feeling unwell, having seizures without fever, loss of consciousness, or head injuries may qualify. It's important that a blood test is done during their medical care, and families must give their consent for their child to participate. The trial is not currently recruiting participants, but it will include all genders. Families considering participation can expect to help advance knowledge in this important area, potentially leading to better detection and response to child abuse in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age : 0-2 y.o
• • Medical consultation for malaise, seizure (without fever), loss of consciousness, traumatic bain injury, or cranioplasty
• • Blood test during medical care
• • Accepted informed consent
• Exclusion Criteria:
• • Refused informed consent
• • For control groups : medical history of child abuse
• • For AHT group : rare metabolic disease (Menkes, etc..)